These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 11724504)
1. Apheresis technology for prevention and regression of atherosclerosis. Yamamoto A; Harada-Shiba M; Kawaguchi A; Tsushima M Ther Apher; 2001 Aug; 5(4):221-5. PubMed ID: 11724504 [TBL] [Abstract][Full Text] [Related]
2. The effect of atorvastatin on serum lipids and lipoproteins in patients with homozyous familial hypercholesterolemia undergoing LDL-apheresis therapy. Yamamoto A; Harada-Shiba M; Kawaguchi A; Oi K; Kubo H; Sakai S; Mikami Y; Imai T; Ito T; Kato H; Endo M; Sato I; Suzuki Y; Hori H Atherosclerosis; 2000 Nov; 153(1):89-98. PubMed ID: 11058703 [TBL] [Abstract][Full Text] [Related]
3. Atorvastatin in low-density lipoprotein apheresis-treated patients with homozygous and heterozygous familial hypercholesterolemia. Goldammer A; Wiltschnig S; Heinz G; Jansen M; Stulnig T; Hörl WH; Derfler K Metabolism; 2002 Aug; 51(8):976-80. PubMed ID: 12145769 [TBL] [Abstract][Full Text] [Related]
4. A case of familial hypercholesterolemia; secession from LDL-apheresis by the drug treatment with potent statin and resin. Shiina Y; Homma Y; Oguma T; Fusegawa Y; Ozawa H; Handa S; Tanabe T Tokai J Exp Clin Med; 2005 Sep; 30(3):149-55. PubMed ID: 16285605 [TBL] [Abstract][Full Text] [Related]
5. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group. Mabuchi H; Koizumi J; Shimizu M; Kajinami K; Miyamoto S; Ueda K; Takegoshi T Am J Cardiol; 1998 Dec; 82(12):1489-95. PubMed ID: 9874053 [TBL] [Abstract][Full Text] [Related]
6. Low-density lipoprotein apheresis: an evidence-based analysis. Medical Advisory Secretariat Ont Health Technol Assess Ser; 2007; 7(5):1-101. PubMed ID: 23074505 [TBL] [Abstract][Full Text] [Related]
7. Long-term effect of low-density lipoprotein apheresis in patients with homozygous familial hypercholesterolemia. Makino H; Harada-Shiba M Ther Apher Dial; 2003 Aug; 7(4):397-401. PubMed ID: 12887721 [TBL] [Abstract][Full Text] [Related]
8. Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia. Marais AD; Naoumova RP; Firth JC; Penny C; Neuwirth CK; Thompson GR J Lipid Res; 1997 Oct; 38(10):2071-8. PubMed ID: 9374129 [TBL] [Abstract][Full Text] [Related]
9. Long-term effect of low-density lipoprotein apheresis on plasma lipoproteins and coronary heart disease in native vessels and coronary bypass in severe heterozygous familial hypercholesterolemia. Richter WO; Donner MG; Höfling B; Schwandt P Metabolism; 1998 Jul; 47(7):863-8. PubMed ID: 9667236 [TBL] [Abstract][Full Text] [Related]
12. Disease control via intensified lipoprotein apheresis in three siblings with familial hypercholesterolemia. Taylan C; Schlune A; Meissner T; Ažukaitis K; Udink Ten Cate FE; Weber LT J Clin Lipidol; 2016; 10(6):1303-1310. PubMed ID: 27919346 [TBL] [Abstract][Full Text] [Related]
13. The role of low density lipoprotein apheresis in the treatment of familial hypercholesterolemia. Thompson GR; Kitano Y Ther Apher; 1997 Feb; 1(1):13-6. PubMed ID: 10225774 [TBL] [Abstract][Full Text] [Related]
14. Treatment of refractory familial hypercholesterolemia by low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. The Liposorber Study Group. Gordon BR; Kelsey SF; Bilheimer DW; Brown DC; Dau PC; Gotto AM; Illingworth DR; Jones PH; Leitman SF; Prihoda JS Am J Cardiol; 1992 Oct; 70(11):1010-6. PubMed ID: 1414897 [TBL] [Abstract][Full Text] [Related]
15. Comparison of different treatment regimens in a case of homozygous familial hypercholesterolemia. Palcoux JB; Meyer M; Jouanel P; Vanlieferinghen P; Malpuech G Ther Apher; 2002 Apr; 6(2):136-9. PubMed ID: 11982954 [TBL] [Abstract][Full Text] [Related]
16. Effects of CS-514 (eptastatin), an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, on serum lipid and apolipoprotein levels in heterozygous familial hypercholesterolemic patients treated by low density lipoprotein (LDL)-apheresis. Mabuchi H; Fujita H; Michishita I; Takeda M; Kajinami K; Koizumi J; Takeda R; Takegoshi T; Wakasugi T; Ueda K Atherosclerosis; 1988 Aug; 72(2-3):183-8. PubMed ID: 3145745 [TBL] [Abstract][Full Text] [Related]
17. Early-onset plasmapheresis and LDL-apheresis provide better disease control for pediatric homozygous familial hypercholesterolemia than HMG-CoA reductase inhibitors and ameliorate atherosclerosis. Dann EJ; Shamir R; Mashiach T; Shaoul R; Badian A; Stravets T; Kerzman Y; Finkelbaum S; Gaitini D; Lorber A; Bonstein L Transfus Apher Sci; 2013 Oct; 49(2):268-77. PubMed ID: 23791799 [TBL] [Abstract][Full Text] [Related]
18. Influence of atorvastatin versus simvastatin on fibrinogen and other hemorheological parameters in patients with severe hypercholesterolemia treated with regular low-density lipoprotein immunoadsorption apheresis. Otto C; Geiss HC; Donner MG; Parhofer KG; Schwandt P Ther Apher; 2000 Jun; 4(3):244-8. PubMed ID: 10910028 [TBL] [Abstract][Full Text] [Related]
19. Treatment of homozygous familial hypercholesterolemia with low density lipoprotein apheresis: a 4 year follow-up study. Fadul JE; Vessby B; Wikström B; Danielson BG Artif Organs; 1997 May; 21(5):364-8. PubMed ID: 9129767 [TBL] [Abstract][Full Text] [Related]